## Christopher J Weir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5503728/publications.pdf

Version: 2024-02-01

118	5,984	40	74
papers	citations	h-index	g-index
125	125	125	9167 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Separation and the information theory surrogate evaluation approach: A penalised likelihood solution. Pharmaceutical Statistics, 2022, 21, 55-68.	1.3	1
2	The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension. Nature Medicine, 2022, 28, 6-7.	30.7	15
3	Multiple secondary outcome analyses: precise interpretation is important. Trials, 2022, 23, 27.	1.6	13
4	Does a screening checklist for complex health and social care needs have potential clinical usefulness for predicting unplanned hospital readmissions in intensive care survivors: development and prospective cohort study. BMJ Open, 2022, 12, e056524.	1.9	2
5	Advance care planning in primary care for patients with gastrointestinal cancer: feasibility randomised trial. British Journal of General Practice, 2022, 72, e571-e580.	1.4	4
6	Density strips: visualisation of uncertainty in clinical data summaries and research findings. BMJ Evidence-Based Medicine, 2022, 27, 373-377.	3.5	0
7	Current recommendations/practices for anonymising data from clinical trials in order to make it available for sharing: A scoping review. Clinical Trials, 2022, 19, 452-463.	1.6	5
8	Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open, 2022, 12, e064173.	1.9	10
9	Informed decisionâ€making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments. Pharmaceutical Statistics, 2022, 21, 740-756.	1.3	7
10	A pragmatic, multi-centered, stepped wedge, cluster randomized controlled trial pilot of the clinical and cost effectiveness of a complex Stroke Oral healthCare intervention pLan Evaluation II (SOCLE II) compared with usual oral healthcare in stroke wards. International Journal of Stroke, 2020, 15, 318-323.	5.9	8
11	Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification. Clinical Trials, 2020, 17, 562-566.	1.6	45
12	NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. American Journal of Neuroradiology, 2020, 41, 2209-2218.	2.4	10
13	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurology, The, 2020, 19, 214-225.	10.2	81
14	A smartphone-based test for the assessment of attention deficits in delirium: A case-control diagnostic test accuracy study in older hospitalised patients. PLoS ONE, 2020, 15, e0227471.	2.5	9
15	Evaluation of surrogacy in the multi-trial setting based on information theory: an extension to ordinal outcomes. Journal of Biopharmaceutical Statistics, 2020, 30, 364-376.	0.8	4
16	Evaluating improvement interventions using routine data to support a learning health system: research design, data access, analysis and reporting. BMJ Quality and Safety, 2020, 29, 696-700.	3.7	2
17	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-72.	0.7	11
18	Delirium detection in older acute medical inpatients: a multicentre prospective comparative diagnostic test accuracy study of the 4AT and the confusion assessment method. BMC Medicine, 2019, 17, 138.	5.5	121

#	Article	IF	Citations
19	How to design a dose-finding study using the continual reassessment method. BMC Medical Research Methodology, 2019, 19, 18.	3.1	56
20	The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials. Multiple Sclerosis Journal, 2019, 25, 1697-1699.	3.0	2
21	Unreported Summary Statistics in Trial Publications and Risk of Bias in Stroke Rehabilitation Systematic Reviews: An International Survey of Review Authors and Examination of Practical Solutions. Journal of Stroke Medicine, 2019, 2, 136-142.	0.3	3
22	The 4  A's test for detecting delirium in acute medical patients: a diagnostic accuracy study. Health Technology Assessment, 2019, 23, 1-194.	2.8	82
23	Palliative care for people with advanced liver disease: A feasibility trial of a supportive care liver nurse specialist. Palliative Medicine, 2018, 32, 919-929.	3.1	37
24	Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine, 2018, 16, 29.	5.5	398
25	Brain natriuretic peptide and high-sensitivity Troponin at 3 hours post emergency department attendance with unexplained syncope predict 90 day outcome. Emergency Care Journal, 2018, 14, .	0.3	0
26	Protocol for validation of the 4AT, a rapid screening tool for delirium: a multicentre prospective diagnostic test accuracy study. BMJ Open, 2018, 8, e015572.	1.9	29
27	Early PREdiction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort study. Intensive Care Medicine, 2018, 44, 1836-1848.	8.2	59
28	Awareness of fetal movements and care package to reduce fetal mortality (AFFIRM): a stepped wedge, cluster-randomised trial. Lancet, The, 2018, 392, 1629-1638.	13.7	128
29	Diagnostic test accuracy of a novel smartphone application for the assessment of attention deficits in delirium in older hospitalised patients: a prospective cohort study protocol. BMC Geriatrics, 2018, 18, 217.	2.7	11
30	The acute medical unit model: A characterisation based upon the National Health Service in Scotland. PLoS ONE, 2018, 13, e0204010.	2.5	6
31	A practical guide to preâ€trial simulations for Bayesian adaptive trials using SAS and BUGS. Pharmaceutical Statistics, 2018, 17, 854-865.	1.3	4
32	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open, 2018, 8, e021944.	1.9	43
33	Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. Journal of Neurology, 2018, 265, 1795-1802.	3.6	7
34	Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review. BMC Medical Research Methodology, 2018, 18, 25.	3.1	226
35	Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Medicine, 2018, 44, 627-635.	8.2	97
36	Functional strength training versus movement performance therapy for upper limb motor recovery early after stroke: a RCT. Efficacy and Mechanism Evaluation, 2018, 5, 1-112.	0.7	12

#	Article	IF	CITATIONS
37	Development of a Bayesian response-adaptive trial design for the Dexamethasone for Excessive Menstruation study. Statistical Methods in Medical Research, 2017, 26, 2681-2699.	1.5	3
38	Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk prediction in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Atherosclerosis, 2017, 264, 67-73.	0.8	16
39	Models for estimating and projecting global, regional and national prevalence and disease burden of asthma: protocol for a systematic review. BMJ Open, 2017, 7, e015441.	1.9	5
40	Promoting Recruitment using Information Management Efficiently (PRIME): study protocol for a stepped-wedge cluster randomised controlled trial within the REstart or STop Antithrombotics Randomised Trial (RESTART). Trials, 2017, 18, 22.	1.6	9
41	Embracing model-based designs for dose-finding trials. British Journal of Cancer, 2017, 117, 332-339.	6.4	47
42	Promoting Recruitment using Information Management Efficiently (PRIME): a stepped-wedge, cluster randomised trial of a complex recruitment intervention embedded within the REstart or Stop Antithrombotics Randomised Trial. Trials, 2017, 18, 623.	1.6	5
43	Home monitoring of breathing rate in people with chronic obstructive pulmonary disease: observational study of feasibility, acceptability, and change after exacerbation. International Journal of COPD, 2017, Volume 12, 1221-1231.	2.3	44
44	Rationale, design and methodology of a trial evaluating three strategies designed to improve sedation quality in intensive care units (DESIST study). BMJ Open, 2016, 6, e010148.	1.9	8
45	Phase 2 Randomised Controlled Trial and Feasibility Study of Future Care Planning in Patients with Advanced Heart Disease. Scientific Reports, 2016, 6, 24619.	3.3	24
46	Predictive value of cell-surface markers in infections in critically ill patients: protocol for an observational study (ImmuNe FailurE in Critical Therapy (INFECT) Study). BMJ Open, 2016, 6, e011326.	1.9	8
47	Staff education, regular sedation and analgesia quality feedback, and a sedation monitoring technology for improving sedation and analgesia quality for critically ill, mechanically ventilated patients: a cluster randomised trial. Lancet Respiratory Medicine, the, 2016, 4, 807-817.	10.7	38
48	The effectiveness and variation of acute medical units: a systematic review. International Journal for Quality in Health Care, 2016, 28, 433-446.	1.8	27
49	Socioeconomic status, comorbidity and mortality in patients with type 2 diabetes mellitus in Scotland 2004–2011: a cohort study. Journal of Epidemiology and Community Health, 2016, 70, 596-601.	3.7	22
50	Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review. Journal of Biopharmaceutical Statistics, 2016, 26, 859-879.	0.8	14
51	Application of Mixed Effects Limits of Agreement in the Presence of Multiple Sources of Variability: Exemplar from the Comparison of Several Devices to Measure Respiratory Rate in COPD Patients. PLoS ONE, 2016, 11, e0168321.	2.5	53
52	Clinical and Cost Effectiveness of Enhanced Oral Healthcare in Stroke Care Settings (SOCLE II): A Pilot, Stepped Wedge, Cluster Randomized, Controlled Trial Protocol. International Journal of Stroke, 2015, 10, 979-984.	5.9	11
53	Prescription of emergency antiepileptic medication after a first childhood seizure: analysis of routine administrative data. Epileptic Disorders, 2015, 17, 172-176.	1.3	2
54	Adaptive clinical trials and their potential to improve drug-development efficiency. Clinical Investigation, 2015, 5, 359-361.	0.0	1

#	Article	IF	CITATIONS
55	Characterization of Inhibitors and Monoclonal Antibodies That Modulate the Interaction between Plasmodium falciparum Adhesin PfRh4 with Its Erythrocyte Receptor Complement Receptor 1. Journal of Biological Chemistry, 2015, 290, 25307-25321.	3.4	12
56	Future Care Planning for patients approaching end-of-life with advanced heart disease: an interview study with patients, carers and healthcare professionals exploring the content, rationale and design of a randomised clinical trial. BMJ Open, 2014, 4, e005021-e005021.	1.9	13
57	N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetologia, 2014, 57, 2505-2512.	6.3	16
58	FAST INdiCATE Trial Protocol. Clinical Efficacy of Functional Strength Training for Upper Limb Motor Recovery Early after Stroke: Neural Correlates and Prognostic Indicators. International Journal of Stroke, 2014, 9, 240-245.	5.9	5
59	RApid Primary care Initiation of Drug treatment for Transient Ischaemic Attack (RAPIDâ^'TIA): study protocol for a pilot randomised controlled trial. Trials, 2013, 14, 194.	1.6	6
60	Principles of dose finding studies in cancer: a comparison of trial designs. Cancer Chemotherapy and Pharmacology, 2013, 71, 1107-1114.	2.3	48
61	Randomised controlled trial of azithromycin in smokers with asthma: Table 1–. European Respiratory Journal, 2013, 42, 1412-1415.	6.7	49
62	The Glasgow Outcome at Discharge Scale: An Inpatient Assessment of Disability after Brain Injury. Journal of Neurotrauma, 2013, 30, 970-974.	3.4	24
63	Improving the Efficiency of Stroke Trials. Stroke, 2013, 44, 3422-3428.	2.0	22
64	Clinical relevance and practical implications of trials of perfusion and angiographic imaging in patients with acute ischaemic stroke: a multicentre cohort imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1001-1007.	1.9	15
65	The Modified Graeb Score. Stroke, 2013, 44, 635-641.	2.0	119
66	Smoking in Asthma Is Associated with Elevated Levels of Corticosteroid Resistant Sputum Cytokines—An Exploratory Study. PLoS ONE, 2013, 8, e71460.	2.5	27
67	Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax, 2012, 67, 502-508.	5.6	68
68	Noninvasive MRI Measurement of CBF: Evaluating An Arterial Spin Labelling Sequence with 99mTc-HMPAO CBF Autoradiography in a Rat Stroke Model. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 973-977.	4.3	19
69	Sensitive troponin assay predicts outcome in syncope. Emergency Medicine Journal, 2012, 29, 1001-1003.	1.0	29
70	Urinary catheterization in acute stroke: clinical realities. A mixed methods study. Clinical Rehabilitation, 2012, 26, 470-479.	2.2	16
71	Nonpharmacological Interventions for Caregivers of Stroke Survivors. Stroke, 2012, 43, .	2.0	9
72	Predictors of upper limb recovery after stroke: a systematic review and meta-analysis. Clinical Rehabilitation, 2012, 26, 291-313.	2.2	303

#	Article	IF	Citations
73	Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: Relationship to disease severity. Journal of Allergy and Clinical Immunology, 2012, 129, 655-663.e8.	2.9	90
74	Bronchial nitric oxide flux (Jâ $\in$ 2aw) is sensitive to oral corticosteroids in smokers with asthma. Respiratory Medicine, 2011, 105, 1823-1830.	2.9	12
75	Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. BMJ Open, 2011, 1, e000101-e000101.	1.9	218
76	Fraud in Clinical Trials. Significance, 2011, 8, 164-168.	0.4	14
77	Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial. BMC Pulmonary Medicine, $2011, 11, 16$ .	2.0	56
78	Timing of Birth and Risk of Multiple Sclerosis in the Scottish Population. European Neurology, 2010, 63, 36-40.	1.4	55
79	Baseline Serum Urate and 90-Day Functional Outcomes following Acute Ischemic Stroke. Cerebrovascular Diseases, 2009, 28, 202-203.	1.7	30
80	Allopurinol and Nitric Oxide Activity in the Cerebral Circulation of Those With Diabetes. Diabetes Care, 2009, 32, 135-137.	8.6	31
81	Results of the MRI Substudy of the Intravenous Magnesium Efficacy in Stroke Trial. Stroke, 2009, 40, 1704-1709.	2.0	15
82	Categorizing Stroke Prognosis Using Different Stroke Scales. Stroke, 2009, 40, 3396-3399.	2.0	118
83	Randomised controlled trial of combined spinal epidural vs. spinal anaesthesia for elective caesarean section: vasopressor requirements and cardiovascular changes. European Journal of Anaesthesiology, 2009, 26, 47-51.	1.7	4
84	Stroke education for healthcare professionals: Making it fit for purpose. Nurse Education Today, 2008, 28, 337-347.	3.3	17
85	The evidence-base for stroke education in care homes. Nurse Education Today, 2008, 28, 829-840.	3.3	12
86	Severity of drug dependence does not predict changes in drug users' behaviour over time. Critical Public Health, 2008, 18, 381-389.	2.4	2
87	Effects of Magnesium Treatment in a Model of Internal Capsule Lesion in Spontaneously Hypertensive Rats. Stroke, 2008, 39, 448-454.	2.0	45
88	Allopurinol Use Yields Potentially Beneficial Effects on Inflammatory Indices in Those With Recent Ischemic Stroke. Stroke, 2008, 39, 3303-3307.	2.0	75
89	Organized Inpatient (Stroke Unit) Care for Stroke. Stroke, 2008, 39, 2402-2403.	2.0	57
90	Magnesium for Treatment of Acute Lacunar Stroke Syndromes. Stroke, 2007, 38, 1269-1273.	2.0	43

#	Article	IF	CITATIONS
91	The Virtual International Stroke Trials Archive. Stroke, 2007, 38, 1905-1910.	2.0	101
92	Does the Prevention of Complications Explain the Survival Benefit of Organized Inpatient (Stroke) Tj ETQq0 0 0 0	rgBT/Over	lock 10 Tf 50
93	Flexible Design and Efficient Implementation of Adaptive Dose-Finding Studies. Journal of Biopharmaceutical Statistics, 2007, 17, 1033-1050.	0.8	17
94	Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Statistics in Medicine, 2006, 25, 183-203.	1.6	150
95	Problem drug users and assault: Response to Galvani. International Journal of Drug Policy, 2006, 17, 250-251.	3.3	1
96	Extended donor criteria in lung transplantation: Impact on organ allocation. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 1154-1160.	0.8	119
97	Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diabetes/Metabolism Research and Reviews, 2006, 22, 79-82.	4.0	54
98	Effect of Smoking Status on Outcome after Acute Ischemic Stroke. Cerebrovascular Diseases, 2006, 21, 260-265.	1.7	39
99	Improving Trial Power Through Use of Prognosis-Adjusted End Points. Stroke, 2005, 36, 597-601.	2.0	36
100	Problem drug users and assault. International Journal of Drug Policy, 2005, 16, 393-402.	3.3	24
101	Comparison of the National Institutes of Health Stroke Scale With Disability Outcome Measures in Acute Stroke Trials. Stroke, 2005, 36, 2187-2192.	2.0	117
102	Design and Analysis of Phase III Trials with Ordered Outcome Scales: The Concept of the Sliding Dichotomy. Journal of Neurotrauma, 2005, 22, 511-517.	3.4	140
103	Elevated Pulse Pressure During the Acute Period of Ischemic Stroke Is Associated With Poor Stroke Outcome. Stroke, 2004, 35, e153-5.	2.0	42
104	Poststroke Neurological Improvement Within 7 Days Is Associated With Subsequent Deterioration. Stroke, 2004, 35, 2165-2170.	2.0	21
105	Targeting Neuroprotection Clinical Trials to Ischemic Stroke Patients With Potential to Benefit From Therapy. Stroke, 2004, 35, 2111-2116.	2.0	29
106	Effects of intrathecal administration of a cell permeant caspase inhibitor, boc-d-fluoromethylketone (BDFMK), on behavioral deficits following spinal cord ischemia: a dose–response analysis. Brain Research, 2003, 959, 183-190.	2.2	11
107	The role of methadone in drug-related deaths in the west of Scotland. Addiction, 2003, 98, 995-1002.	3.3	68
108	Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial. Statistics in Medicine, 2003, 22, 705-726.	1.6	82

#	Article	IF	CITATIONS
109	Serum Urate as an Independent Predictor of Poor Outcome and Future Vascular Events After Acute Stroke. Stroke, 2003, 34, 1951-1956.	2.0	287
110	Strengthening Acute Stroke Trials Through Optimal Use of Disability End Points. Stroke, 2003, 34, 2676-2680.	2.0	49
111	Effect of Area-Based Deprivation on the Severity, Subtype, and Outcome of Ischemic Stroke. Stroke, 2003, 34, 2623-2628.	2.0	71
112	Effect of Blood Pressure During the Acute Period of Ischemic Stroke on Stroke Outcome. Stroke, 2003, 34, 2420-2425.	2.0	143
113	Low Triglyceride, Not Low Cholesterol Concentration, Independently Predicts Poor Outcome following Acute Stroke. Cerebrovascular Diseases, 2003, 16, 76-82.	1.7	72
114	Inter-relationships between spinal cord blood flow, neuronal death and neurological function in rabbit spinal cord ischemia. Brain Research, 2002, 946, 43-51.	2.2	19
115	Prognostic value of single-photon emission tomography in acute ischaemic stroke. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 21-26.	2.1	21
116	Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. BMJ: British Medical Journal, 1997, 314, 1303-1303.	2.3	438
117	Influence of cholesterol on survival after stroke: retrospective study. BMJ: British Medical Journal, 1997, 314, 1584-1584.	2.3	95
118	Comparison of mean cerebral transit time and single-photon emission tomography for estimation of stroke outcome. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1261-1267.	2.1	9